Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Alnylam Announces Encouraging Exploratory Cardiac Endpoint Data For Patisiran in hATTR Amyloidosis
Alnylam Announces Encouraging Exploratory Cardiac Endpoint Data For Patisiran in hATTR Amyloidosis
Alnylam Announces Encouraging Exploratory Cardiac Endpoint Data For Patisiran in hATTR Amyloidosis
Submitted by
admin
on September 14, 2018 - 9:40am
Source:
CP Wire
News Tags:
Alnylam
Patisiran
hATTR amyloidosis
Onpattro
Headline:
Alnylam Announces Encouraging Exploratory Cardiac Endpoint Data For Patisiran in hATTR Amyloidosis
snippet:
In post-hoc analysis, the exposure-adjusted rates of all-cause death and/or hospitalization were reduced approximately 50% in patients receiving Patisiran vs placebo
hATTR amyloidosis affects approximately 50,000 people worldwide
Do Not Allow Advertisers to Use My Personal information
